vs

Side-by-side financial comparison of PATTERSON UTI ENERGY INC (PTEN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

PATTERSON UTI ENERGY INC is the larger business by last-quarter revenue ($1.1B vs $622.0M, roughly 1.8× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -2.2%, a 36.6% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -12.7%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -8.4%).

Patterson UTI Energy Inc. is a leading oilfield services provider offering onshore contract drilling, pressure pumping, well completion and related support services. It primarily serves upstream oil and gas operators across North America, operating in major unconventional resource basins including shale and tight gas formations.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

PTEN vs RPRX — Head-to-Head

Bigger by revenue
PTEN
PTEN
1.8× larger
PTEN
$1.1B
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+17.5% gap
RPRX
4.8%
-12.7%
PTEN
Higher net margin
RPRX
RPRX
36.6% more per $
RPRX
34.4%
-2.2%
PTEN
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-8.4%
PTEN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PTEN
PTEN
RPRX
RPRX
Revenue
$1.1B
$622.0M
Net Profit
$-24.5M
$214.2M
Gross Margin
Operating Margin
62.4%
Net Margin
-2.2%
34.4%
Revenue YoY
-12.7%
4.8%
Net Profit YoY
-170.8%
2.9%
EPS (diluted)
$-0.06
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PTEN
PTEN
RPRX
RPRX
Q1 26
$1.1B
Q4 25
$1.1B
$622.0M
Q3 25
$1.2B
$609.3M
Q2 25
$1.2B
$578.7M
Q1 25
$1.3B
$568.2M
Q4 24
$1.1B
$593.6M
Q3 24
$1.3B
$564.7M
Q2 24
$1.3B
$537.3M
Net Profit
PTEN
PTEN
RPRX
RPRX
Q1 26
$-24.5M
Q4 25
$-9.2M
$214.2M
Q3 25
$-36.4M
$288.2M
Q2 25
$-49.1M
$30.2M
Q1 25
$1.0M
$238.3M
Q4 24
$-51.4M
$208.2M
Q3 24
$-978.8M
$544.0M
Q2 24
$11.1M
$102.0M
Operating Margin
PTEN
PTEN
RPRX
RPRX
Q1 26
Q4 25
-0.0%
62.4%
Q3 25
-2.4%
70.1%
Q2 25
-2.4%
36.3%
Q1 25
1.3%
94.0%
Q4 24
-2.7%
60.9%
Q3 24
-73.8%
Q2 24
3.4%
50.2%
Net Margin
PTEN
PTEN
RPRX
RPRX
Q1 26
-2.2%
Q4 25
-0.8%
34.4%
Q3 25
-3.1%
47.3%
Q2 25
-4.1%
5.2%
Q1 25
0.1%
41.9%
Q4 24
-4.5%
35.1%
Q3 24
-72.9%
96.3%
Q2 24
0.8%
19.0%
EPS (diluted)
PTEN
PTEN
RPRX
RPRX
Q1 26
$-0.06
Q4 25
$-0.01
$0.49
Q3 25
$-0.10
$0.67
Q2 25
$-0.13
$0.07
Q1 25
$0.00
$0.55
Q4 24
$-0.10
$0.46
Q3 24
$-2.50
$1.21
Q2 24
$0.03
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PTEN
PTEN
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$3.2B
$9.7B
Total Assets
$5.4B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PTEN
PTEN
RPRX
RPRX
Q1 26
Q4 25
$418.5M
$618.7M
Q3 25
$184.8M
$938.9M
Q2 25
$183.8M
$631.9M
Q1 25
$223.1M
$1.1B
Q4 24
$239.2M
$929.0M
Q3 24
$113.4M
$950.1M
Q2 24
$72.4M
$1.8B
Total Debt
PTEN
PTEN
RPRX
RPRX
Q1 26
Q4 25
$1.2B
$9.0B
Q3 25
$1.2B
$8.9B
Q2 25
$1.2B
$8.0B
Q1 25
$1.2B
$7.6B
Q4 24
$1.2B
$7.6B
Q3 24
$1.2B
$7.6B
Q2 24
$1.2B
$7.6B
Stockholders' Equity
PTEN
PTEN
RPRX
RPRX
Q1 26
$3.2B
Q4 25
$3.2B
$9.7B
Q3 25
$3.2B
$9.6B
Q2 25
$3.3B
$9.5B
Q1 25
$3.4B
$9.8B
Q4 24
$3.5B
$10.3B
Q3 24
$3.6B
$10.3B
Q2 24
$4.6B
$9.8B
Total Assets
PTEN
PTEN
RPRX
RPRX
Q1 26
$5.4B
Q4 25
$5.6B
$19.6B
Q3 25
$5.5B
$19.3B
Q2 25
$5.6B
$18.3B
Q1 25
$5.8B
$17.6B
Q4 24
$5.8B
$18.2B
Q3 24
$6.0B
$18.0B
Q2 24
$7.0B
$17.7B
Debt / Equity
PTEN
PTEN
RPRX
RPRX
Q1 26
Q4 25
0.38×
0.92×
Q3 25
0.38×
0.93×
Q2 25
0.37×
0.84×
Q1 25
0.36×
0.78×
Q4 24
0.36×
0.74×
Q3 24
0.35×
0.74×
Q2 24
0.27×
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PTEN
PTEN
RPRX
RPRX
Operating Cash FlowLast quarter
$63.9M
$827.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
4.9%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PTEN
PTEN
RPRX
RPRX
Q1 26
$63.9M
Q4 25
$397.5M
$827.1M
Q3 25
$215.8M
$702.6M
Q2 25
$139.7M
$364.0M
Q1 25
$208.1M
$596.1M
Q4 24
$315.8M
$742.5M
Q3 24
$296.3M
$703.6M
Q2 24
$197.5M
$658.2M
Free Cash Flow
PTEN
PTEN
RPRX
RPRX
Q1 26
Q4 25
$259.0M
Q3 25
$71.3M
Q2 25
$-4.5M
Q1 25
$46.3M
Q4 24
$175.5M
Q3 24
$115.7M
Q2 24
$67.0M
FCF Margin
PTEN
PTEN
RPRX
RPRX
Q1 26
Q4 25
22.6%
Q3 25
6.1%
Q2 25
-0.4%
Q1 25
3.7%
Q4 24
15.3%
Q3 24
8.6%
Q2 24
5.0%
Capex Intensity
PTEN
PTEN
RPRX
RPRX
Q1 26
4.9%
Q4 25
12.1%
Q3 25
12.3%
Q2 25
11.9%
Q1 25
12.8%
Q4 24
12.2%
Q3 24
13.5%
Q2 24
9.8%
Cash Conversion
PTEN
PTEN
RPRX
RPRX
Q1 26
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
207.11×
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
17.83×
6.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PTEN
PTEN

Segment breakdown not available.

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons